Introduction
In 1929 Weiss, Robb, and Blumgart reported that intravenously administered histamine produced a fall in ventilatory capacity of asthmatic subjects at dosage levels which did not affect the pulmonary ventilation in normal subjects. This hypersensitivity to histamine of the airways in asthmatic subjects has often been confirmed (Curry, 1946; Dowell, Kerr, and Park, 1966) and has been shown to persist for many years even in the absence of active asthma (Bouhuys et al., 1960) .
Certain animal species develop histamine hypersensitivity after an injection of a vaccine prepared from Bordetella pertussis organisms (Parfenjev and Goodline, 1948) , and while investigating this phenomenon in the laboratory Fishel, Szentivanyi, and Talmage (1962) observed that in some species histamine hypersensitivity could be produced by the administration of the beta-adreI)ergic blocking drug dichloroisoproterenol. These authors went on to suggest that the histamine hypersensitivity was the result of a functional imbalance between the two types (alpha and beta) of adrenergic receptor systems, and Szentivanyi (1968) developed this hypothesis into a general theory to explain the atopic abnormality in bronchial asthma. In man the clinical importance of these experimental observations became evident when McNeill (1964) reported that propranolol, a beta-adrenergic receptor blocking drug, caused a fall in ventilatory capacity in asthmatic subjects which was not reversed by isoprenaline. McNeill and Ingram (1966) , using a body plethysmograph, further demonstrated increased airways resistance in normal subjects when given propranolol. On the other hand, Zaid and Beall (1966) were unable to show increased bronchial sensitivity to histamine in normal subjects with beta-adrenergic receptor blockade.
Here we report on an investigation designed to assess the relationship of alpha-adrenergic receptors in bronchial smooth muscle to histamine hypersensitivity in patients with bronchial asthma. In addition, it is shown that disodium cromoglycate inhibits the hypersensitivity to histamine of bronchial smooth muscle in patients with asthma. Table II . In these patients the fall in V.C. and F.E.V.1 due to histamine was completely inhibited (Fig. 1) . A paired t test shows that there was no significant difference in the V.C. and F.E.V.1 at 0 time and 40 minutes, but at 5, 10, and 20 minutes there was a significant difference in both V.C. and F.E.V., when compared with the control test. 
Discussion
The effect of histamine on smooth muscle may be produced by a direct action of the amine on bronchial smooth musdle or by a delayed reflex action (DeKock, Nadel, Zwi, Golebatch, and Olsen, 1966) . Our investigation has again confirmed that patients with asthma have a bronchial smooth muscle which is hypersensitive to histamine. We have not been able to show a similar fall in ventilatory capacity to histamine by this method in patients with chronic bronchitis (unpublished observations). The mechanism of this histamine hypersensitivity in bronchial asthma is not clear. Little attention has been paid to the possibility that bronchial smooth muscle has alpha-adrenergic receptor sites, but alpha-receptor sites do exist on the bronchial smooth muscle of certain animal species (Castro de la Mata, Penna, and Aviado, 1962; Everitt and Cairncross, 1969) . Both phentolamine and phenoxybenzamine are classified as alpha-receptor blocking drugs. Phentolamine, which is an imidazole (as is histamine), has a direct effect on the adrenal medulla, releasing noradrenaline. During the test with phentolamine the patients experienced a mild tachycardia but so long as they remained seated during the test there was no fall in blood pressure. It is unlikely that the inhibition of the histamine effect on ventilatory capacity in these patients was mediated via the adrenal medulla. This view would seem to be confirmed by the results obtained with phenoxybenzamine.
Though this drug gave rise to tachycardia, hypotension was not a problem during the test period, as the patients remained at rest. Further, phenoxybenzaeine does not have a direct action on the adrenal medulla. Phenoxybenzamine has an antihistamine effect which cannot be dissociated from its .alpha-adrenergic blocking activity (Goodman and Gilman, 1965) . It is difficult to assess the many pharmacological effects which have. been reported due to phentolamine and phenoxybenzamine. Nevertheless, our results suggest that the bronchial smooth muscle of patients with asthma have alpha-adrenergic. receptor sites and that blockade of these sites with alpha-receptor antagonists alters the sensitivity of the bronchial smooth muscle to histamine.
Disodium cromoglycate was introduced for the treatment of patients with allergic bronchial asthma by Howell and Altounyan (1967) . On inhalation disodium cromoglycate can inhibit the fall in V.C. and F.E.V., in patients with allergic asthma when challenged by inhalation of the appropriate antigen (Pepys, Hargreave, Chan, and McCarthy, 1968) . This drug has also been shown to inhibit the fall in V.C. and F.E.V.i in exercise-induced asthma (Davies, 1968) . On the other hand, disodium crQmoglycate has been reported not to affect the histamine respone of human bronchial smooth muscle (Cox, 1967) . We have investigated the effect of this drug on the phenomenon of histamine hypersensitivity in patients with bronchial asthma and have found disodium cromoglycate is a potent inhibitor of the fall in ventilatory capacity produced in these subjects by an intravenous infusion of histamine.
The mechanism by which disodium cromoglycate produces its effect in bronchial asthma remains obscure. The drug inhibits the release of pharmacologically active amines following the antigen-antibody reaction (Cox, 1967) . The release of these amines after the antigen-antibody reaction in anaphylaxis is dependent on three factors: calcium, a heat-labile factor, and free sulphydryl groups (Mongar and Schild, 1957; Austen and Humphrey, 1961) . Though in some animal species intravenous disodium cromoglycate does give rise to profound reflex cardiovascular changes (Cox, 1967) , it is unlikely that disodium cromoglycate acts as an alpha-receptor blocking drug as. cardiovascular effects have not been reported in man.
The alpha-and beta-adrenergic receptors are believed to control the ionized calcium concentration in the environment of the contractile protein of the myofibrils (Filo, Bohr, and Ruegg, 1965; Bohr, 1967) , and the histamine response of smooth muscle is dependent on the concentration of ionized calcium (Daniel, 1964) . It can therefore be postulated that beta-receptor blocking drugs by increasing the ionized calcium of smooth muscle fibrils increase the histamine response, and that the alpha-receptor blocking drugs by lowering the ionized calcium inhibit the histamine response of bronchial smooth muscle. One explanation of our observations is that disodium cromoglycate stabilizes the cell membrane and this alters calcium ion transport. Such an effect would explain both the inhibition of amine release after the antigenantibody reaction and the inhibition of histamine hypersensitivity of bronchial smooth muscle affected by this drug. Further investigation of the mechanism of action of disodium cromoglycate should lead to a better understanding of the nature of bronchial asthma.
